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Abstract
Background: Given the relationship between iron metabolism and lead toxicokinetics, we hypothesized that
polymorphisms in iron metabolism genes might modify maternal-fetal lead transfer. The objective of this study was
to determine whether maternal and/or infant transferrin (TF) and hemochromatosis (HFE) gene missense variants
modify the association between maternal blood lead (MBL) and umbilical cord blood lead (UCBL).
Methods: We studied 476 mother-infant pairs whose archived blood specimens were genotyped for TF P570S, HFE
H63D and HFE C282Y. MBL and UCBL were collected within 12 hours of delivery. Linear regression models were used to
examine the association between log-transformed MBL and UCBL, examine for confounding and collinearity, and
explore gene-environment interactions.
Results: The geometric mean MBL was 0.61 μg/dL (range 0.03, 3.2) and UCBL 0.42 (<0.02, 3.9). Gene variants were
common with carrier frequencies ranging from 12-31%; all were in Hardy-Weinberg equilibrium. In an adjusted linear
regression model, log MBL was associated with log UCBL (β=0.92, 95% CI: 0.82, 1.03; p<0.01) such that a 1% increase
in MBL was associated with a 0.92% increase in UCBL among infants born to wild-type mothers. In infants born
to C282Y variants, however, a 1% increase in MBL is predicted to increase UCBL 0.65% (βMain Effect = −0.002, 95%
CI: −0.09, −0.09; p=0.97; βInteraction= −0.27, 95% CI: −0.52, −0.01; p=0.04), representing a 35% lower placental
lead transfer among women with MBL 5 μg/dL.
Conclusions: Maternal HFE C282Y gene variant status is associated with greater reductions in placental transfer of
lead as MBL increases. The inclusion of gene-environment interaction in risk assessment models may improve
efforts to safeguard vulnerable populations.
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Background
Nearly 1% of women aged 20–39 living in the United
States have a blood lead concentration (BPb) greater
than or equal to 5 μg/dL (n =420,000) [1,2]. Due to lead
transfer across the placenta, their children are at risk of
being born with BPb above the CDC reference level of
5 μg/dL [3] and are being exposed to a neurotoxicant,
for which no threshold for harmful effects has been
identified [4], at a period of heightened vulnerability
[5,6].
Prenatal lead exposure is linked to spontaneous abor-
tion [7], low birth weight [8], preterm birth [9], small for
gestational age birth [10], congenital malformation
[8,11], and deficits in intellectual development [12-15].
The transfer of lead across the placenta from mother to
fetus is complex and incompletely understood, but is the
sole factor determining fetal exposure. Sources of
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exposure) or intrinsic (via mobilization of lead in bone
stores).
The mechanisms for placental uptake and efflux of lead
are not well defined, but likely include metal-specific pro-
teins and receptors common to iron metabolism. Hence,
genes that regulate iron metabolism may play an import-
ant role in placental lead transfer. Transferrin (TF)a n d
hemochromatosis (HFE) are two iron metabolism genes
for which functional variants are prevalent in North
America. The TF gene is located on 3q22.1 and codes for
the glycoprotein transferrin, which is responsible for inter-
cellular iron transport [16]. While the TF gene is highly
polymorphic, a common variant is the P570S missense
single nucleotide polymorphism (SNP) [17]. The preva-
lence of the P570S polymorphism is estimated at 15% in
the US general population and 12.5% in Native Americans,
though the latter is based on a small sample [17].
The HFE gene is located on 6p21.3 and codes for the
HFE protein, which regulates iron cellular uptake by bind-
ing transferrin and decreasing activation of transferrin
receptors, thereby reducing transport across cellular mem-
branes [18]. HFE protein influences the expression of
other metal transporters found in the intestinal tract such
as divalent metal transporter 1 (DMT1) [19,20]. Two mis-
sense SNPs (H63D and C282Y)i nt h eHFE gene are over-
represented among individuals with the hemochromatosis
phenotype in which iron is hyperabsorbed. In a large
screening study based in North America, 24% of whites
and 20% of Native Americans carried variants for H63D,
while 10% of whites and 5% of Native Americans carried
variants for C282Y [21].
Though iron metabolism genes play a role in lead me-
tabolism and toxicity among children and adults [22-29],
it remains unclear how normal adaptations in homeo-
static function and physiology during pregnancy may
complicate the relationship between iron metabolism
genes, maternal BPb, and maternal-fetal lead transfer.
The objective of this study is to determine whether gen-
omic variations in maternal and/or infant TF and HFE
genes modify the association between maternal and um-
bilical cord blood lead.
Methods
Study participants
Subjects were enrolled in a prospective birth cohort study
based around the Tar Creek Superfund Site (TCSS) in
northeastern Oklahoma. The site is a former lead and zinc
mega-mine that was in operation from 1891-1970s [30].
Lead, cadmium and manganese are among the toxic metals
that contaminate its estimated 50 square miles. As part of
a collaborative effort between the Harvard School of Public
Health (HSPH; Boston, MA, USA), a community-based
non-profit – Local Environmental Action Demanded
Agency (LEAD; Miami, OK, USA), and Integris Baptist
Regional Health Center (IBRHC; Oklahoma City, OK,
USA), a birth cohort was established in 2002 to study early
life exposure to metals, psychosocial stress, and their inter-
actions on neurocognitive development. The Institutional
Review Boards at HSPH and IBRHC approved the research
protocol.
Between 2002 and 2007, 713 pregnant women present-
ing for prenatal care or delivery to the only hospital in
Ottawa County (Integris Baptist Regional Health Center;
Miami, OK, USA) were enrolled in the cohort. Eligibility
criteria were: 1) giving birth at the Integris Hospital in
Miami, OK; 2) intention to reside in the area for the fol-
lowing two years; 3) not already enrolled in the study
with another child; and 4) being proficient in English.
After confirming study eligibility and providing informed
consent, participants provided demographic, medical and
environmental information via standardized, interviewer-
administered questionnaires. Delivery room staff gathered
anthropometric measures on newborns within twelve
hours of birth. Deoxyribonucleic acid (DNA) was ex-
tracted on a subset of the first 500 children born. We lim-
ited our analysis to the 476 singleton pregnancies in which
both mother and infant were successfully genotyped for
the SNPs of interest.
Blood measurements
Umbilical cord and maternal venous whole blood was
collected in trace element-free tubes (BD Vacutainer®
reference number 368380; Becton Dickinson, Franklin
Lakes, NJ, USA) and tubes for DNA extraction (PAXgene®
Blood DNA Tubes; PreAnalytiX GmbH, Hombrechtikon,
Switzerland) within twelve hours of delivery. Samples were
frozen and subsequently shipped in batches to the Trace
Metals Laboratory at HSPH for analysis. All sample prep-
aration and handling occurred in a Class 10,000 clean
room (ISO 7), under a Class 100 clean hood (ISO 5). One
gram of whole blood from each sample was digested in
1 mL of concentrated nitric acid for 24 hours. After add-
ing 0.5 mL of 30% hydrogen peroxide, the samples were
diluted with deionized water to a final volume of 10 mL.
Blood lead was measured using an inductively-coupled
plasma mass spectrometer (ICP-MS, Elan 6100; Perkin
Elmer, Norwalk, CT, USA).
Quality control measures included analysis of initial
and continuous calibration verification standards, pro-
cedural blanks, duplicate samples, and spiked samples.
Comparisons were drawn from National Institute of
Standards and Technology Standard Reference Material
for trace elements in water (NIST SRM 1643d) and lead
in blood (NIST SRM 955b). The average of five replicate
measurements was reported as the final value. The lower
limit of detection (LOD) was 0.02 micrograms lead per
deciliter whole blood.
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High-molecular-weight DNA was extracted from white
blood cells of archived umbilical cord blood with com-
mercially available PureGene Kits (Gentra Systems,
Minneapolis, MN, USA). After DNA quantification,
samples were adjusted to TE (Tris-EDTA) buffer, parti-
tioned into aliquots, and stored at −80°C. Multiplex
polymerase chain reaction assays were designed using
Sequenom SpectroDESIGNER software by inputting se-
quence containing the SNP site and 100 base pairs of
flanking sequence on either side of the SNP. Three
SNPs were multiplexed: (TF) P570S (rs1049296), (HFE)
H63D (rs1799945), and (HFE) C282Y (rs1800562). The
extension product was then spotted onto a 384 well
spectroCHIP before being flown in the MALDI-TOF
mass spectrometer.
Potential confounders
While covariates that are extrinsic to the maternal-fetal
system, such as socioeconomic status, would not theor-
etically confound the relationship between maternal and
umbilical cord blood lead, factors that are intrinsic to
this system may do just that. A woman’s iron status, for
example, is associated with her iron metabolism geno-
type and may also impact placental lead transfer by in-
fluencing the expression of metal transport machinery
that is common to both iron and lead.
Regardless of theoretical plausibility, we assessed sev-
eral covariates for potential confounding of the associ-
ation between maternal and umbilical cord blood lead.
Infant gestational age, birth weight, and gender were
considered in a sensitivity analysis, as were maternal
race, ethnicity, and socioeconomic status. Adjustments
for anemia and iron status were also made using the co-
variates for which maximum data were available: serum
ferritin in infants, and hematocrit in both infants and
mothers.
Statistical analysis
We examined summary statistics and distributional plots
for all variables prior to analysis. Two blood lead values
that were reported as negative values were converted to
the instrument LOD divided by the square root of two.
We calculated the arithmetic and geometric means and
standard deviations of blood lead levels stratified by
genotype (wild-type versus carrier), testing for signifi-
cance using Student’s t-test for independent samples.
We inspected the distributions of TF and HFE genotypes
and tested their frequencies for deviation from the
Hardy-Weinberg principle using Pearson’s chi-square
test. Given that the allele frequencies were relatively low,
we chose dominant genetic models for each allele,
combining heterozygotes and homozygote variants into
a single indicator term.
Blood lead levels followed a log normal distribution
and were transformed in order to satisfy the normality
condition for regression analysis. As a result, beta coeffi-
cients from regression models represent the percent
change in UCBL for a 1% change in MBL. An a priori
type I error rate (ʱ) of 0.05 was set for all tests.
We first explored the relationship between umbilical
cord and maternal venous blood lead through a bivariate
analysis limited to mother-infant pairs in which both
mother and infant were wild-type (n=159). The linear
relationship between these two variables informed our
choice to analyze the full dataset using linear models.
Next, we re-ran bivariate models using the entire cohort
(n=476) and evaluated for potential confounding using
the aforementioned independent variables. Confounders
were included in subsequent regression models if they
changed the parameter estimate for the main effect by at
least 10%.
We tested for effect modification by genotype and in-
cluded interaction terms for all combinations of mater-
nal and infant genotype and maternal blood lead.
Separate models were built for infants and mothers in
order to assess each group independently. Lastly, infant
and maternal interaction terms were combined into a
final multivariable regression model. Given the potential
for collinearity between maternal and infant genotype in
this final model, correlations between independent vari-
ables and collinearity diagnostics were examined; an a
priori variance inflation factor threshold was set at 10.
Regression diagnostics were run on all models.
Data were analyzed using SPSS Statistics for Windows,
Version 19.0 (IBM Corporation, Armonk, NY, USA) and
R Version 2.15.3 (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Descriptive characteristics for mothers and infants from
the original birth cohort are listed in Table 1, stratified
by the availability of genotype information. Our study
cohort is limited to the 476 mother-infant pairs in whom
blood lead levels and genotype information was deter-
mined. The mean weight, length, and head circumference
of neonates corresponded to World Health Organization
international growth charts, which are recommended by
the CDC for use in children up to age 24 months [31].
Genotype frequencies for all 476 mother-infant pairs
were successfully determined for all three SNPs. The
genotype frequencies for mothers and infants are shown
in Tables 2 and 3, respectively; all were found to be in
Hardy-Weinberg equilibrium (ʱ =0.05). There were no
statistically significant differences between geometric
mean blood lead values when stratified by variant status.
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information
a
Characteristic Complete genotype information Unavailable genotype information
n=476 Descriptive measure
b n=232 Descriptive measure
b
Mothers
Age at birth of infant (years) 476 24.5 (5.5) 228 24.6 (5.2)
Race/Ethnicity
c
White 341 70% 185 79%
Native American 120 25% 65 28%
Hispanic 24 5% 4 1.7%
Asian 16 3.3% 3 1.3%
African American 4 0.8% 1 0.4%
Education
< 12th grade 118 25% 66 28%
≥ 12th grade 358 75% 166 72%
Hematocrit at delivery (%) 468 34.3 (3.8) 225 34 (3.4)
Hematocrit at 28 weeks gestation (%) 409 35.5 (3.4) 197 34.9 (3.3)
Blood lead at delivery (μg/dL)
d 476 0.61 (1.87) 183 0.54 (1.7)
Infants
Gender (% female) 475 45% 230 48%
Gestational age (weeks) 473 39.2 (1.3) 229 38.8 (1.5)
Birth weight (g) 476 3385 (485) 229 3300 (438)
Birth length (cm) 464 49.8 (3) 227 50.4 (2.4)
Birth head circumference (cm) 458 34.7 (2.3) 225 34.3 (2)
Hematocrit at birth (%) 132 55.2 (7.8) 225 55.9 (7.2)
Serum ferritin at birth (ng/mL) 244 154 (92) 177 156 (97)
Umbilical cord blood lead (μg/dL)
d 476 0.42 (2.12) 180 0.38 (1.8)
aComplete data are missing for certain characteristics;
bArithmetic mean ± SD or% as indicated;
cOverlap between categories exists because individuals could
self-identify as belonging to two or more races;
dGeometric mean ± GSD.
Table 2 Maternal genotype frequencies and geometric mean blood lead levels for dominant models
a,b
Single-nucleotide polymorphism No. Genotype frequencies Dominant modeling Geometric mean BLL
c (95% CI
d)
TF P570S (rs1049296)
Homozygous wild-type 355 CC= 0.75 wild-type 0.62 (0.58, 0.66)
Heterozygous 109 CT=0.23
variant 0.60 (0.55, 0.67)
Homozygous variant 12 TT=0.02
HFE H63D (rs1799945)
Homozygous wild-type 350 HH=0.74 wild-type 0.61 (0.57, 0.65)
Heterozygous 117 HD=0.24
variant 0.62 (0.56, 0.69)
Homozygous variant 9 DD=0.02
HFE C282Y (rs1800562)
Homozygous wild-type 417 CC= 0.88 wild-type 0.62 (0.58, 0.65)
Heterozygous 55 CY=0.11
variant 0.60 (0.51, 0.70) Homozygous variant 4 YY=0.01
aAll genotype frequencies are in Hardy-Weinberg equilibrium (α=0. 05 );
bNone of the differences in geometric mean BLL by variant status are statistically significant;
cblood lead level (μg/dL);
dconfidence interval.
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infant pairs (n=157), MBL was linearly associated with
UCBL (ʲ =0.79; 95% CI 0.69, 0.88; p <0.001). When this
analysis was repeated for the log-transformed values, the
correlation between these two variables strengthened
(ʲ= 0.99; 95% CI 0.88, 1.10; p<0.001). Similar parameter
estimates were obtained when the bivariate analysis was
expanded to include all 476 mother-infant dyads (data
not shown).
In our sensitivity analysis, the association between ma-
ternal and umbilical cord blood lead was not con-
founded by gestational age, birth weight, infant gender,
maternal race/ethnicity, socioeconomic status, and in-
fant hematocrit or serum ferritin. While the parameter
estimate for maternal hematocrit at delivery was statisti-
cally significant (ʲ =−0.008; 95% CI −0.01, −0.003;
p< 0.01), it did not meaningfully change the beta estimate
for MBL (ʲadjusted=0.84; 95% CI 0.77, 0.92; p<0.001;
ʲunadjusted=0.85; 95% CI 0.78, 0.93; p<0.001). Therefore,
it did not satisfy the a priori definition for confounding.
Lead-hematocrit interaction terms were also modeled
under the premise that hematocrit might modify placental
lead transfer if, for example, varying amounts of lead cross
the placenta in the presence of low or normal hematocrit.
The interaction between MBL and both maternal
hematocrit at delivery (ʲInteraction=−0.02; 95% CI −0.04,
0.001; p=0.06), as well as maternal hematocrit at 28 weeks
(ʲInteraction=−0.02; 95% CI −0.05, 0.003; p=0.08) were
marginally significant. While the interaction between MBL
and umbilical cord hematocrit at birth (ʲInteraction=−0.03;
95% CI −0.04, −0.01; p=0.001) was statistically significant,
this result should be interpreted with caution; since umbil-
ical cord hematocrit was not routinely measured, the sam-
ple available for analysis was limited to only 132 of the
original 476 study participants.
Lastly, we explored the potential for a gene-environment
interaction between iron metabolism genotype and MBL by
regressing log-transformed values of UCBL on similarly-
transformed values of MBL. In order to account for poten-
tial confounding between genotype variants, the main effect
terms for maternal and infant TF and HFE variant status,
along with their respective interaction with MBL, were
modeled together. Though infant and maternal variant
status were modestly correlated for each gene variant
(Spearman ˁ ranging from 0.43 to 0.52), variance inflation
factors did not exceed 3.4 and thus raised little suspicion
for collinearity. This conclusion was strengthened by two
additional observations: 1) parameter estimates remained
stable when potentially collinear variables were selectively
excluded from the full model described in Table 4 and
2) in regression models that were limited to either infant
or maternal gene variants (Additional files 1 and 2,
respectively), the main effect and interaction term param-
eter estimates were very similar to those from the full
regression model.
In a fully-adjusted model accounting for infant and
maternal iron metabolism genotype and gene-environment
interaction terms, MBL retained its association with UCBL
(ʲ= 0.92; 95% CI 0.82, 1.03; p<0.001; Table 4). Among
wild-type mother-infant pairs, a 1% increase in MBL is ex-
pected to increase UCBL by 0.92%. The association be-
tween UCBL and MBL was not modified by infant gene
variant status or infant genotype-MBL interaction terms
(Figure 1). Likewise, maternal gene variant main effect
terms were not significant. However, the interaction be-
tween maternal HFE C282Ygenotype and MBL was signifi-
cant (ʲInteraction=−0.27; 95% CI −0.52, −0.01; p= 0.04;
Table 4) and attenuated the relationship between UCBL
and MBL (Figure 2). While the other two maternal geno-
type interaction terms were not statistically significant, all
Table 3 Infant genotype frequencies and geometric mean umbilical cord blood lead levels for dominant models
a,b
Single-nucleotide polymorphism No. Genotype frequencies Dominant modeling Geometric mean BLL
c (95% CI
d)
TF P570S (rs1049296)
Homozygous wild-type 338 CC= 0.71 wild-type 0.43 (0.40, 0.47)
Heterozygous 129 CT=0.27
variant 0.40 (0.36, 0.46)
Homozygous variant 9 TT=0.02
HFE H63D (rs1799945)
Homozygous wild-type 330 HH=0.69 wild-type 0.44 (0.40, 0.48)
Heterozygous 132 HD=0.28
variant 0.39 (0.35, 0.44)
Homozygous variant 14 DD=0.03
HFE C282Y (rs1800562)
Homozygous wild-type 415 CC= 0.87 wild-type 0.42 (0.39, 0.46)
Heterozygous 58 CY=0.12
variant 0.43 (0.36, 0.51) Homozygous variant 3 YY=0.01
aAll genotype frequencies are in Hardy-Weinberg equilibrium (α =0.05);
bNone of the differences in geometric mean BLL by variant status are statistically
significant;
cblood lead level (μg/dL);
dconfidence interval.
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UCBL (Figure 3). Notably, these results did not differ ap-
preciably from output generated by the two regression
models that were limited to either infant or maternal gene
variants (see Additional files 1 and 2, respectively).
Among infants born to mothers who have the HFE
C282Y variant, a 1% increase in MBL is predicted to in-
crease UCBL by 0.65%, as opposed to 0.92% for infants
born to mothers who are wild-type. Factoring the log
transformation, our model predicts that for two pregnant
women with BPb 5 μg/dL but differing HFE C282Y geno-
types, UCBL will be 3 μg/dL (95% CI 2.3, 3.9) in the infant
born to the wild-type mother and 1.95 μg/dL (95% CI 0.8,
4.7) in the infant born to the mother carrying the HFE
C282Y variant.
Discussion
The results of this study suggest that maternal iron me-
tabolism genotype is a modifier of placental lead trans-
fer. Infants born to women with the HFE C282Y gene
variant have lower umbilical cord blood lead concentra-
tions. Further, the attenuating impact of this gene-
environment interaction on placental lead transfer
strengthens as MBL rises. While MBL seems to be the
key determinant of UCBL, maternal iron metabolism
gene variants modify this relationship in a manner that is
potentially clinically significant in exposed populations.
Additional results suggest that fetal iron metabolism
gene variant status did not modify the relationship be-
tween UCBL and MBL. In other words, it appears that
lead transfer across the placenta is not altered signifi-
cantly by fetal iron metabolism genes, but primarily by
maternal genotype. This finding has direct relevance for
explaining the biology that underlies placental lead
transfer.
Table 4 Multivariable regression model of iron
metabolism gene variants, log-transformed maternal
blood lead, and their interaction on log-transformed
umbilical cord blood lead (n=476)
a,b,c
Predictor β 95% CI P-value
Constant −0.17 −0.21, −0.13 <0.01
Maternal Blood Lead (MBL) 0.92 0.82, 1.03 <0.01
Maternal TF P570S 0.04 −0.03, 0.11 0.28
MBL × Maternal TF P570S −0.13 −0.35, 0.09 0.24
Maternal HFE H63D −0.07 −0.14, 0.01 0.08
MBL × Maternal HFE H63D −0.12 −0.34, 0.11 0.32
Maternal HFE C282Y −0.002 −0.09, 0.09 0.97
MBL × Maternal HFE C282Y −0.27 −0.52, −0.01 0.04
Infant TF P570S −0.06 −0.13, 0.003 0.06
MBL × Infant TF P570S −0.03 −0.24, 0.18 0.81
Infant HFE H63D 0.01 −0.06, 0.08 0.77
MBL × Infant HFE H63D 0.10 −0.11, 0.32 0.34
Infant HFE C282Y −0.02 −0.11, 0.07 0.65
MBL × Infant HFE C282Y −0.05 −0.28, 0.17 0.64
aBlood lead concentrations are log-transformed, beta coefficients are therefore
interpreted as percent change in umbilical cord blood lead for a 1% change in
maternal blood lead;
bCollinearity diagnostics indicate a maximum variance
inflation factor of 3.4;
cR
2 for the model equals 0.53 and adjusted R
2 equals
0.52;
dbolded values are statistically significant at α= 0.05.
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Figure 1 Modification by infant genotype of the association between maternal and umbilical cord blood lead. Adjusted for maternal
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influence lead toxicokinetics and toxicodynamics: delta-
aminolevulinic acid dehydratase (ALAD), vitamin D re-
ceptor (VDR), TF and HFE [22,32]. Genetic variability
may influence bioavailability and susceptibility in a
complex fashion, interrelating with other individual
characteristics such as age and micronutrient status to
produce differential outcomes. For example, studies
have shown that while elderly men who carry HFE gene
variants have lower tibia, patella, and blood lead con-
centrations than wild-type subjects [23], children who
carry either HFE or TF variants have higher BPb than
wild-type peers [22]. Moreover, the impact of iron me-
tabolism gene variants on lead metabolism seems to be
amplified in the presence of multiple genotypic variant al-
leles, akin to a dose–response relationship [22,24,25].
While the role of iron metabolism gene variants in pri-
mary lead exposure and bioaccumulation has been stud-
ied, relatively little is known about how maternal and
fetal genetic polymorphisms affect lead transfer across
the placenta. This study adds to the existing literature by
providing evidence that fetal lead exposure is attenuated
among children born to mothers who carry variants for
maternal iron metabolism genes.
The strong association between umbilical cord and
maternal blood lead seen in this cohort has been
observed in many studies [33-36]. However, the toxicoki-
netics of placental lead transfer are not well understood.
Lead uptake by the placenta occurs passively [37] and is
likely influenced by several proteins including, for ex-
ample: HFE protein, which is expressed on the apical
plasma membrane of placental syncytiotrophoblasts near
the maternal circulation, and which interacts with trans-
ferrin to regulate cellular iron absorption [38]; DMT1,
an iron transport protein that is also found in syncytio-
trophoblasts and other tissues, and that plays a vital role
in iron homeostasis [39-42]; and metallothioneins, which
are small, cysteine-rich proteins found in abundance in
placental tissue, have high metal binding properties, and
participate in metal storage and detoxification [43-45].
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Figure 2 Modification by maternal genotype of the association between maternal and umbilical cord blood lead. *p< 0.05. Adjusted for
infant genotype. Three values ≤0.005 ug/dL for umbilical lead not shown.
Figure 3 Gene-environment interaction coefficient estimates
from a model regressing umbilical cord on maternal
blood lead.
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[5]. Though the basolateral iron exporter ferroportin
seems to be the sole cellular iron transporter [46], it
may or may not play a role in lead transport.
Placental iron transfer occurs at the apical plasma mem-
brane of syncytiotrophoblasts via transferrin receptor-
mediated endocytosis. Since HFE protein is expressed at
this site and is physically associated with the transferrin
receptor, it has been hypothesized that HFE protein regu-
lates the transfer of iron from maternal to fetal circulation
[38]. While wild-type HFE protein binds to ʲ2 microglobu-
lin and is transported to the cell surface where it interacts
with transferrin to regulate iron, these normal functions
are altered in individuals who carry the HFE C282Y gene
mutation. Given that lead is carried by these same iron
transporters and receptors, it is possible that functional
perturbations in the HFE protein resulting from HFE
C282Ygene mutations may modify placental lead transfer.
Other hypotheses may also explain the biologic basis
for decreased placental lead transfer among women who
carry iron metabolism gene variants. For example, these
women are more likely to have heightened pre-
pregnancy stores of iron, which may decrease expression
of metal-specific transporters or proteins and thereby
lessen gastrointestinal lead absorption. Another potential
explanation is the creation of a lead-sink in which lead
moves freely into placental tissues via up-regulation of
metal transport mechanisms [26] but is slow to exit into
the fetal circulation due to changes in expression of pro-
teins that bind lead. Perhaps by saturating these trans-
porters, higher maternal levels of micronutrients –
specifically zinc and manganese –reduce lead transfer to
the fetus [34].
Other research in this area has shown that genetic
polymorphisms in iron metabolism genes not only mod-
ify lead kinetics, but also confer variable host response
to lead exposure. Carriers of the TF P570S gene variant,
for example, lose significantly more IQ points per unit
of blood lead than children with wild-type genotypes
[27]. Lead-related decreases in birth weight [28], ad-
vancement of cognitive decline [24], widening of pulse
pressure [29], and prolongation of the QT-interval [25]
have been shown to be amplified in HFE gene variant
carriers.
This study has several limitations. Whereas lead toxi-
cokinetics are likely influenced by an array of functional
gene polymorphisms, such as those involved in calcium
regulation, we investigated only a few iron-specific can-
didate genes. Other genetic variants may modify placen-
tal transfer as well, but we did not have sufficient
information in our dataset to examine them. Addition-
ally, genes in linkage disequilibrium with the HFE gene
might explain our results. Such confounding is unlikely,
however, because other known iron transport genes are
not located in this genomic region and HFE C282Y is a
well-characterized functional variant.
Though it is characteristic of the US population, the
narrow range of exposure among women in this study
limits our ability to extrapolate findings to populations
that have higher average blood lead levels. While re-
sidual confounding is possible, any environmental factor
that confounded our findings would have to be associ-
ated with both placental lead transfer and HFE genotype.
Apart from micronutrient status of iron and calcium, for
example, it seems unlikely that there are environmental
factors that could be associated with both placental lead
transfer and HFE genotype. Introducing additional bio-
markers of iron and calcium sufficiency might clarify the
influence of maternal and fetal micronutrient status on
placental lead transfer.
Statistical considerations include the possibility that
the significant interaction between MBL and maternal
HFE C282Y may be due to a Type I error related to mul-
tiple testing. Conversely, a Type II error due to insufficient
power may explain why the remaining gene-environment
interaction parameter estimates were no different from
the null. Finally, like all new findings, these results require
validation in other cohorts.
When taken in the context of current trends in clin-
ical medicine and population health, the results of this
s t u d yh a v ei n t e r e s t i n gi m p l i cations. Identifying factors
that modify placental lead transfer might inform re-
search in the emerging era of genomic medicine, where
targeted therapeutics hold the promise of lessening the
morbidity associated with prenatal lead exposure. In-
formation about genetic modifiers of lead transfer may
also inform how clinicians will advise, treat, and moni-
tor their pregnant patients for micronutrient deficien-
cies. From a regulatory standpoint, results of this study
prompt us to reconsider the current approach to risk
assessment and ask whether methods should consist-
ently address issues of genetic susceptibility.
Conclusion
This study is among the first to investigate how mater-
nal and fetal genetic polymorphisms secondarily affect
lead transfer across the placenta. Through gene-
environment interaction, maternal iron metabolism
genotype appears to play a role in maternal-fetal lead
transfer. We found that infants born to mothers with
the HFE C282Y gene variant had lower umbilical cord
blood lead levels relative to those born to women who
were wild-type. Moreover, reductions in the propor-
tion of maternal blood lead transferred across the pla-
centa were greatest for infants whose mothers had
higher blood lead levels. The incorporation of gene-
environment information into risk assessment may
Karwowski et al. Environmental Health 2014, 13:77 Page 8 of 10
http://www.ehjournal.net/content/13/1/77improve regulatory efforts to safeguard the health of
vulnerable populations.
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